» Articles » PMID: 31989034

Manipulation of the Dually Thermoresponsive Behavior of Peptide-based Vesicles Through Modification of Collagen-like Peptide Domains

Overview
Date 2020 Jan 29
PMID 31989034
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Materials that respond to temporally defined exogenous cues continue to be an active pursuit of research toward on-demand nanoparticle drug delivery applications, and using one or more exogenous temperature stimuli could significantly expand the application of nanoparticle-based drug delivery formulations under both hyperthermal and hypothermal conditions. Previously we have reported the development of a biocompatible and thermoresponsive elastin--collagen-like polypeptide (ELP-CLP) conjugate that is capable of self-assembling into vesicles and encapsulating small molecule therapeutics that can be delivered at different rates via a single temperature stimulus. Herein we report the evaluation of multiple ELP-CLP conjugates, demonstrating that the inverse transition temperature ( ) of the ELP-CLPs can be manipulated by modifying the melting temperature ( ) of the CLP domain, and that the overall hydrophilicity of the ELP-CLP conjugate also may alter the . Based on these design parameters, we demonstrate that the ELP-CLP sequence (VPGFG)-(GPO)GG can self-assemble into stable vesicles at 25°C and dissociate at elevated temperatures by means of the unfolding of the CLP domain above its . We also demonstrate here for the first time the ability of this ELP-CLP vesicle to dissociate via a hypothermic temperature stimulus by means of exploiting the inverse transition temperature ( ) phenomena found in ELPs. The development of design rules for manipulating the thermal properties of these bioconjugates will enable future modifications to either the ELP or CLP sequences to more finely tune the transitions of the conjugates for specific biomedical applications.

Citing Articles

Supramolecular Assembly and Thermogelation Strategies Using Peptide-Polymer Conjugates.

Pascouau C, Schweitzer M, Besenius P Biomacromolecules. 2024; 25(5):2659-2678.

PMID: 38663862 PMC: 11095398. DOI: 10.1021/acs.biomac.4c00031.


Controlled Release of Drugs from Extracellular Matrix-Derived Peptide-Based Nanovesicles through Tailored Noncovalent Interactions.

Huang H, Hwang J, Anilkumar S, Kiick K Biomacromolecules. 2024; 25(4):2408-2422.

PMID: 38546162 PMC: 11661555. DOI: 10.1021/acs.biomac.3c01361.


Encoding Structure in Intrinsically Disordered Protein Biomaterials.

Strader R, Shmidov Y, Chilkoti A Acc Chem Res. 2024; 57(3):302-311.

PMID: 38194282 PMC: 11354101. DOI: 10.1021/acs.accounts.3c00624.


Controlled Delivery of Vancomycin from Collagen-tethered Peptide Vehicles for the Treatment of Wound Infections.

Hwang J, Huang H, Sullivan M, Kiick K Mol Pharm. 2023; 20(3):1696-1708.

PMID: 36707500 PMC: 10197141. DOI: 10.1021/acs.molpharmaceut.2c00898.


Synthesis of Small Peptide Nanogels Using Radiation Crosslinking as a Platform for Nano-Imaging Agents for Pancreatic Cancer Diagnosis.

Kimura A, Arai T, Ueno M, Oyama K, Yu H, Yamashita S Pharmaceutics. 2022; 14(11).

PMID: 36365217 PMC: 9696042. DOI: 10.3390/pharmaceutics14112400.


References
1.
Wu Y, MacKay J, McDaniel J, Chilkoti A, Clark R . Fabrication of elastin-like polypeptide nanoparticles for drug delivery by electrospraying. Biomacromolecules. 2008; 10(1):19-24. PMC: 2820340. DOI: 10.1021/bm801033f. View

2.
Haney M, Klyachko N, Zhao Y, Gupta R, Plotnikova E, He Z . Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015; 207:18-30. PMC: 4430381. DOI: 10.1016/j.jconrel.2015.03.033. View

3.
Rodriguez-Cabello J, Prieto S, Reguera J, Arias F, Ribeiro A . Biofunctional design of elastin-like polymers for advanced applications in nanobiotechnology. J Biomater Sci Polym Ed. 2007; 18(3):269-86. DOI: 10.1163/156856207779996904. View

4.
Cheng R, Meng F, Deng C, Klok H, Zhong Z . Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials. 2013; 34(14):3647-57. DOI: 10.1016/j.biomaterials.2013.01.084. View

5.
Xu J, Liu Y, Li Y, Wang H, Stewart S, Van der Jeught K . Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nat Nanotechnol. 2019; 14(4):388-397. PMC: 6449187. DOI: 10.1038/s41565-019-0381-6. View